Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 13 of 13 for “"Ranibizumab"”.
-
Grosor macular luego de tratamiento con Ranibizumab o Bevacizumab en degeneración macular relacionada con la edad
… (VEGF) entre los cuales se encuentra el Ranibizumab y el Bevacizumab. El seguimiento se hace mediante medidas funcionales (agudeza visual) y anatómicas (grosor macular por tomografía óptica coherente). Objetivo: comparar el comportamiento del grosor macular luego del tratamiento con cada …
-
Estudio de la influencia de los polimorfismos genéticos en la respuesta a tratamiento con ranibizumab en la degeneración macular asociada a la edad.
… endotelial vascular (VEGF), como es el caso de ranibizumab. El objetivo de este trabajo es evaluar la relación entre la respuesta al tratamiento antiangiogénico en pacientes con DMAE exudativa y los polimorfismos en los genes ADAMTS9/ADAMTS9-AS2 (rs 6795735), COL8A1L/FILIP1L (rs13081855), TGFBR1 …
-
Efecto del tratamiento anti-veg sobre los factores de riesgo cardiovascular y biomarcadores de de estrés oxidativo en pacientes con degeneración macular exudativa asociada a la edad
… y analizar el efecto de la terapia anti-VEGF (Ranibizumab y Pegaptanib) sobre biomarcadores de estrés oxidativo y factores de RCV. MATERIAL Y MÉTODOS La muestra poblacional está constituida por 163 individuos con DMAE y 170 individuos sanos, a los cuales se determino el RCV. A continuación, se …
-
Effect of Drugs on Rabbit Retina
… but it does not affect retinal morphology. Ranibizumab, bevacizumab, and pegaptanib are inhibitors of the cytokine vascular endothelial growth factor. Pegaptanib and ranibizumab are approved for injection into the vitreous. Bevacizumab is a cancer drug injected off-label intravitreally. In …
-
Biomarcadores sanguíneos predictivos de respuesta al tratamiento anti-VEGF en degeneración macular asociada a la edad
… con DMAE neovascular, antes del tratamiento con ranibizumab, para identificar biomarcadores de respuesta a este fármaco. Un modelo de clasificación compuesto por 4 ácidos ribonucleicos (RNA) y 1 micro RNA (miRNA) aislado de PBMCs fue capaz de predecir la respuesta a ranibizumab con alta precisión …
-
Development of polymeric nanoparticulate formulation encapsulating protein molecules following hydrophobic ion pairing complexation
… on optimized parameters with IgG-Fab fragment, ranibizumab (Lucentis®), an anti-VEGF antibody fragment used for the treatment of age-related macular degeneration, loaded nanoparticulate formulation was also successfully developed. Developed nanoparticles formulations were characterized with …
-
Anti-vascular endothelial growth factor in ophthalmology
… were conceived. Pegaptanib, bevacizumab, ranibizumab, aflibercept, and the more recently authorized brolucizumab and faricimab, have all undergone rigorous trials and are now used to treat a vast array of conditions, both on-label and off-label, with more studies underway to further expand …
-
Factores pronósticos en la agudeza visual final de pacientes con oclusión venosa retiniana tratados con terapia antiangiogénica
… con terapia antiangiogénica intravitrea con ranibizumab y bevacizumab tomados retrospectivamente entre 2010 y 2012. Posteriormente se realizó un estudio analítico de cohorte retrospectiva, para establecer la asociación y predicción de los cambios de la agudeza visual. Resultados: se encontró …
-
Current therapeutic approaches for retinopathy of prematurity
… του VEGF (anti-VEGF), όπως το bevacizumab και το ranibizumab, έχουν μεταμορφώσει τη διαχείριση της οπισθίας μορφής της νόσου (ζώνη I και επιθετική οπίσθια ROP), προσφέροντας ταχεία υποστροφή της νόσου plus και καλύτερη διατήρηση του περιφερικού αμφιβληστροειδούς. Ωστόσο, αυτές οι θεραπείες …
-
Genotypes of SNPs of Key Genes Regulate Susceptibility and Drug Sensitivity to Neovascular AMD
… the effectiveness and safety of conbercept and ranibizumab; thirdly, analyzing the association between gene SNPs and nAMD etiology and drug efficacy. Significant genotype differences were found, underscoring the potential of genotype-based personalized treatments for enhanced clinical outcomes …
-
Multifocal pupillographic objective perimetry in age-related maculopathy
… retinal dysfunction following 3 months of ranibizumab therapy confirmed our previous results. What was striking was the revelation that prior to treatment, the delay of pupillary responses to multifocal stimuli were the most vulnerable in AMD, and demonstrated the largest improvement …
-
Multifocal pupillographic objective perimetry in age-related maculopathy
… retinal dysfunction following 3 months of ranibizumab therapy confirmed our previous results. What was striking was the revelation that prior to treatment, the delay of pupillary responses to multifocal stimuli were the most vulnerable in AMD, and demonstrated the largest improvement …
-
Long Term Ocular Drug Delivery with Novel Pentablock Copolymers; Part I: Composite Nanoformulation of Macromolecules For Back of the Eye Diseases, Part II: Dexamethasone Nanoparticle to Develop an In Vitro Model for Glaucoma
… pattern of macromolecules (lysozyme, IgG-Fab, ranibizumab and IgG). The macromolecules encapsulated in PB NPs were prepared by W1/O/W2 double emulsion solvent evaporation method. The macromolecules were optimized to achieve a high drug loading (~17%) and entrapment efficiency (~66%) in the NPs. …